$ENTA
ENANTA PHARMACEUTICALS INC

2017 Q3 Form 10-K Financial Statement

#000156459018030275 Filed on November 29, 2018

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2017 Q1
Revenue $75.93M $7.511M $8.959M
YoY Change 491.29% -46.27% -31.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.120M $5.230M $5.460M
YoY Change 15.32% 22.2% 23.25%
% of Gross Profit
Research & Development $16.51M $15.41M $13.00M
YoY Change 43.57% 42.88% 42.23%
% of Gross Profit
Depreciation & Amortization $570.0K $550.0K $530.0K
YoY Change 26.67% 25.0% 23.26%
% of Gross Profit
Operating Expenses $21.63M $20.64M $13.00M
YoY Change 35.7% 91.38% 42.23%
Operating Profit -$9.506M
YoY Change 1582.48%
Interest Expense $660.0K $600.0K $8.000K
YoY Change 40.43% 5354.55% -27.27%
% of Operating Profit
Other Income/Expense, Net $660.0K $600.0K $549.0K
YoY Change 40.13% 34.23% 16.31%
Pretax Income $54.96M -$12.53M -$8.957M
YoY Change -2189.73% 1851.71% 9531.18%
Income Tax -$18.45M $4.103M $3.565M
% Of Pretax Income -33.56%
Net Earnings $36.51M -$8.426M -$5.392M
YoY Change -2125.97% 683.09% 227.78%
Net Earnings / Revenue 48.08% -112.18% -60.19%
Basic Earnings Per Share $1.91 -$0.44 -$0.28
Diluted Earnings Per Share $1.86 -$0.44 -$0.28
COMMON SHARES
Basic Shares Outstanding 19.08M 19.05M
Diluted Shares Outstanding 19.05M

Balance Sheet

Concept 2017 Q3 2017 Q2 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $223.7M $192.0M $175.6M
YoY Change 6.46% -12.13% -20.33%
Cash & Equivalents $65.68M $22.26M $19.21M
Short-Term Investments $158.0M $169.8M $156.4M
Other Short-Term Assets $3.500M $6.600M $6.100M
YoY Change -61.96% -29.03% -34.41%
Inventory
Prepaid Expenses
Receivables $10.61M $7.500M $8.959M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $237.8M $206.1M $190.6M
YoY Change 2.44% -14.76% -21.46%
LONG-TERM ASSETS
Property, Plant & Equipment $8.049M $8.100M $8.526M
YoY Change 0.56% 8.01% 10.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $70.00M $43.30M $65.30M
YoY Change 118.07% 65.27% 159.13%
Other Assets $10.70M $18.30M $14.50M
YoY Change 18.89% 181.54% 141.67%
Total Long-Term Assets $88.82M $69.70M $88.37M
YoY Change 80.81% 73.62% 126.99%
TOTAL ASSETS
Total Short-Term Assets $237.8M $206.1M $190.6M
Total Long-Term Assets $88.82M $69.70M $88.37M
Total Assets $326.6M $275.8M $279.0M
YoY Change 16.13% -2.18% -0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.714M $5.500M $4.056M
YoY Change 9.98% 169.08% 57.7%
Accrued Expenses $7.970M $5.600M $5.098M
YoY Change 76.64% 22.19% 93.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $20.98M $11.10M $9.154M
YoY Change 165.97% 16.0% -23.64%
LONG-TERM LIABILITIES
Long-Term Debt $1.100M $600.0K $600.0K
YoY Change 83.33% 0.0% -14.29%
Other Long-Term Liabilities $2.410M $3.300M $2.355M
YoY Change 18.02% 68.11% 29.9%
Total Long-Term Liabilities $2.410M $3.900M $2.355M
YoY Change 18.02% 98.68% 29.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.98M $11.10M $9.154M
Total Long-Term Liabilities $2.410M $3.900M $2.355M
Total Liabilities $24.96M $15.00M $12.95M
YoY Change 120.1% 16.04% -14.71%
SHAREHOLDERS EQUITY
Retained Earnings $45.36M $17.27M
YoY Change 64.06% -43.41%
Common Stock $256.4M $248.8M
YoY Change 5.85% 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $301.7M $260.9M $266.0M
YoY Change
Total Liabilities & Shareholders Equity $326.6M $275.8M $279.0M
YoY Change 16.13% -2.18% -0.94%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2017 Q1
OPERATING ACTIVITIES
Net Income $36.51M -$8.426M -$5.392M
YoY Change -2125.97% 683.09% 227.78%
Depreciation, Depletion And Amortization $570.0K $550.0K $530.0K
YoY Change 26.67% 25.0% 23.26%
Cash From Operating Activities $57.30M -$4.790M -$3.010M
YoY Change -2790.14% 127.01% -129.92%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$740.0K -$580.0K
YoY Change -42.86% 21.31% -61.59%
Acquisitions
YoY Change
Other Investing Activities -$14.67M $8.400M $2.380M
YoY Change 155.57% -127.26% 124.53%
Cash From Investing Activities -$14.90M $7.660M $1.800M
YoY Change 142.67% -124.37% -491.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.010M 190.0K -210.0K
YoY Change 1342.86% -90.31% -139.62%
NET CHANGE
Cash From Operating Activities 57.30M -4.790M -3.010M
Cash From Investing Activities -14.90M 7.660M 1.800M
Cash From Financing Activities 1.010M 190.0K -210.0K
Net Change In Cash 43.41M 3.060M -1.420M
YoY Change -629.39% -109.69% -114.02%
FREE CASH FLOW
Cash From Operating Activities $57.30M -$4.790M -$3.010M
Capital Expenditures -$240.0K -$740.0K -$580.0K
Free Cash Flow $57.54M -$4.050M -$2.430M
YoY Change -3464.91% 170.0% -121.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2017 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
202000
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19423949
CY2018Q1 dei Entity Public Float
EntityPublicFloat
1280474378
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63902000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65675000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
244828000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
157994000
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67205000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10614000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4454000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3536000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
380389000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
237819000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
16389000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
70038000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8374000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8049000
CY2018Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
8375000
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
10123000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92000
CY2018Q3 us-gaap Assets
Assets
414227000
CY2017Q3 us-gaap Assets
Assets
326637000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4745000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3714000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9892000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1690000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-286000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102814000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88268000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40461000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2506000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35402000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4572000
CY2018Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1388000
CY2017Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
9298000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57451000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23441000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20749000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16966000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
118297000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
78200000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16025000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20982000
CY2017Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
807000
CY2018Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1628000
CY2017Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
762000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2895000
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2410000
CY2018Q3 us-gaap Liabilities
Liabilities
20548000
CY2017Q3 us-gaap Liabilities
Liabilities
24961000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
194000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
191000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
276526000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256241000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-398000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-112000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
117357000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
45356000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
393679000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
301676000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
414227000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
326637000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19395000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19120000
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19395000
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19120000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
206625000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94856000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
57427000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
88328000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
24614000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
30841000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4852000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2492000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1026000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
236157000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9354000
CY2018 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
319000
CY2017 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
1229000
CY2016 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
518000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
835000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-702000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1511000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
918000
CY2016 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
1747000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
269936000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1079000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13071000
CY2017 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
213000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-131000
CY2018 enta Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
6244000
CY2018 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1756000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15845000
CY2018 us-gaap Profit Loss
ProfitLoss
71956000
CY2017 us-gaap Profit Loss
ProfitLoss
17710000
CY2016 us-gaap Profit Loss
ProfitLoss
21666000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
9354000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1661000
CY2016 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-2294000
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
213000
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1747000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1317000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1843000
CY2018 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7910000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
564000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
92000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29220000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
52653000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
35809000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
260682000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
249305000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
153504000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2981000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43663000
CY2018 enta Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
6244000
CY2017 enta Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
1079000
CY2016 enta Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
1026000
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
213000
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1747000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1756000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
202000
CY2018 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
79000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
73000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
68000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4409000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1017000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2705000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1773000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
49098000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16577000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21726000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
26088000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
1588000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
318000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enanta Pharmaceuticals, Inc. (the &#8220;Company&#8221;), incorporated in Delaware in 1995, is <font style="Background-color:#FFFFFF;color:#000000;">a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily for the treatment of viral infections and liver diseases. The Company discovered glecaprevir, the second</font><font style="font-size:12pt;"> </font><font style="Background-color:#FFFFFF;color:#000000;">protease inhibitor discovered and developed through its collaboration with&#160;AbbVie, which is marketed as part of AbbVie&#8217;s direct-acting antiviral (DAA) regimen under the tradenames MAVYRET&#8482; (U.S.) or MAVIRET&#8482; (ex-U.S.) (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C virus, or HCV. The other protease inhibitor under its HCV collaboration, which is part of AbbVie&#8217;s initial DAA regimens for the treatment of chronic HCV, is currently marketed outside the U.S. under the tradename VIEKIRAX<sup style="font-size:85%; vertical-align:top">&#174; </sup>(paritaprevir/ritonavir/ombitasvir). </font><font style="color:#000000;">Royalties from the Company&#8217;s AbbVie collaboration and its existing financial resources provide funding to support its wholly-owned research and development programs</font><font style="Background-color:#FFFFFF;color:#000000;">, which are currently focused on the following disease targets</font>: respiratory syncytial virus (&#8220;RSV&#8221;),&#160;non-alcoholic steatohepatitis (&#8220;NASH&#8221;); primary biliary cholangitis (&#8220;PBC&#8221;); and hepatitis B virus (&#8220;HBV&#8221;).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to many of the risks common to companies in the biotechnology industry including, but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital, adequate personnel infrastructure, and extensive compliance reporting capabilities.</p>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to,&#160;<font style="Background-color:#FFFFFF;">management&#8217;s judgments with respect to its revenue arrangements; valuation of warrants, Series&#160;1 nonconvertible preferred stock and stock-based awards; the accrual of research and development expenses, and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets.&#160;</font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Customers and Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company has all cash and investment balances at one accredited financial institution, including cash in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has historically generated all of its revenue from its collaborative research and license agreements as well as a U.S. government contract (see Note 7). As of September 30, 2018 and 2017, accounts receivable consisted of amounts due from the Company&#8217;s principal collaborator (see Note 7). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is completely dependent on third-party manufacturers for product supply for preclinical and clinical research activities in its non-partnered programs. The Company relies and expects to continue to rely exclusively on several manufacturers to supply the Company with its requirements for the active pharmaceutical ingredients related to these programs. These research programs would be adversely affected by a significant interruption in the supply of its active pharmaceutical ingredients. </p>
CY2018 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2017 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2016 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
323227000
CY2018Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1628000
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
280651000
CY2017Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1569000
CY2018 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2017 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2016 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2018 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2017-10-04
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
261791000
CY2018 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2018 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
575000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
261217000
CY2017Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
228211000
CY2017 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
9000
CY2017 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
188000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
228032000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17466000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15103000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9092000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7054000
CY2018Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3617000
CY2017Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3156000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3274000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2829000
CY2018Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1901000
CY2017Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1130000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
507000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
456000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
593000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
399000
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1792000
CY2017Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1175000
CY2018Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
593000
CY2017Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
676000
CY2018Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
293000
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
379000
CY2018Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
217000
CY2017Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
180000
CY2015Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1775000
CY2016 enta Warrants Granted
WarrantsGranted
0
CY2016 enta Warrants Expired
WarrantsExpired
0
CY2016Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1775000
CY2017 enta Warrants Granted
WarrantsGranted
0
CY2017 enta Warrants Expired
WarrantsExpired
0
CY2017 enta Warrants Exercised
WarrantsExercised
745000
CY2017Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1030000
CY2018 enta Warrants Granted
WarrantsGranted
0
CY2018 enta Warrants Expired
WarrantsExpired
52000
CY2018 enta Warrants Exercised
WarrantsExercised
978000
CY2015Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2016Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2017 enta Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
0.01
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0177
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.60
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7705000
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
295000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
295000
CY2017Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2018 enta Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
0.01
CY2018 enta Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
0.01
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0229
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.57
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2298000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
606000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
229000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
51000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2624000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2624000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1646000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.36
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
57.96
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
27.23
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
48.74
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.65
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
36.65
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.84
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37821000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
129115000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
129115000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
88289000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14180000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1503000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6243000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1079000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1026000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
31.84
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.52
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.12
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15845000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13071000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9354000
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30064000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1395000
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
341000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2161000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1475000
CY2018 enta Number Of Leases
NumberOfLeases
2
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2033000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2025000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2025000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2209000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2728000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2803000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
513000
CY2017Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1026000
CY2018Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
145000
CY2017Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
188000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2684000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
608000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
519000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11551000
CY2018Q3 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
86000
CY2018Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
93000
CY2018Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
101000
CY2018Q3 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
99000
CY2018Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
379000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
16449000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
10078000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
12233000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2858000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
813000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
956000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2245000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1503000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2136000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-387000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-151000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-159000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.245
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.052
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.074
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.038
CY2018 enta Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
0.042
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.028
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.045
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.030
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.227
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.343
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.335
CY2018Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7372000
CY2017Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7899000
CY2018Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
756000
CY2017Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1001000
CY2018Q3 enta Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
223000
CY2017Q3 enta Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1199000
CY2018Q3 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
139000
CY2017Q3 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
67000
CY2018Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
828000
CY2017Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1171000
CY2018Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9318000
CY2017Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11337000
CY2017Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2018Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9318000
CY2017Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11337000
CY2018Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
798000
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1175000
CY2018Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
943000
CY2017Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1214000
CY2018Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
8375000
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10123000
CY2016Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
745000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
563000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
134000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
355000
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
59000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
59000
CY2018Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1679000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
852000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
712000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38109000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44049000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57262000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67205000
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
23732000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
27190000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
34622000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
32753000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
960000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1066000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1338000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1429000
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3644000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5370000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3690000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8461000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
11693000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
12555000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
20288000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
27420000
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.61
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
CY2016Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10417000
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8959000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7511000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75927000
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
17463000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
18465000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
20640000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
21632000
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
524000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
549000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
600000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
660000
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1542000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3565000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4103000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18447000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4980000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5392000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-8426000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
36508000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86

Files In Submission

Name View Source Status
0001564590-18-030275-index-headers.html Edgar Link pending
0001564590-18-030275-index.html Edgar Link pending
0001564590-18-030275.txt Edgar Link pending
0001564590-18-030275-xbrl.zip Edgar Link pending
enta-10k_20180930.htm Edgar Link pending
enta-20180930.xml Edgar Link completed
enta-20180930.xsd Edgar Link pending
enta-20180930_cal.xml Edgar Link unprocessable
enta-20180930_def.xml Edgar Link unprocessable
enta-20180930_lab.xml Edgar Link unprocessable
enta-20180930_pre.xml Edgar Link unprocessable
enta-ex1010_399.htm Edgar Link pending
enta-ex211_13.htm Edgar Link pending
enta-ex231_8.htm Edgar Link pending
enta-ex311_10.htm Edgar Link pending
enta-ex312_11.htm Edgar Link pending
enta-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grj0oxpge3j0000001.jpg Edgar Link pending
grj0oxpge3j0000002.jpg Edgar Link pending
grj0oxpge3j0000003.jpg Edgar Link pending
gztwt2xipuho000001.jpg Edgar Link pending
gztwt2xipuho000002.jpg Edgar Link pending
gztwt2xipuho000003.jpg Edgar Link pending
gztwt2xipuho000004.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending